Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, Bieber T, Misery L, Wollenberg A, Reich A, Ahmad F, Piketty C. Ständer S, et al. Among authors: misery l. N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316. N Engl J Med. 2020. PMID: 32074418 Clinical Trial.
Clinical classification of itch: a position paper of the International Forum for the Study of Itch.
Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, Bergasa NV, Gieler U, Misery L, Wallengren J, Darsow U, Streit M, Metze D, Luger TA, Greaves MW, Schmelz M, Yosipovitch G, Bernhard JD. Ständer S, et al. Among authors: misery l. Acta Derm Venereol. 2007;87(4):291-4. doi: 10.2340/00015555-0305. Acta Derm Venereol. 2007. PMID: 17598029 Free article.
Putative neuronal mechanisms of sensitive skin.
Ständer S, Schneider SW, Weishaupt C, Luger TA, Misery L. Ständer S, et al. Among authors: misery l. Exp Dermatol. 2009 May;18(5):417-23. doi: 10.1111/j.1600-0625.2009.00861.x. Exp Dermatol. 2009. PMID: 19382311 Review.
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, Lacour JP, D'Incan M, Dupin N, Sassolas B, Misery L, Chevrant-Breton J, Lebrun-Vignes B, Desseaux K, Valeyre D, Revuz J, Tazi A, Chosidow O, Dupuy A. Droitcourt C, et al. Among authors: misery l. Chest. 2014 Oct;146(4):1046-1054. doi: 10.1378/chest.14-0015. Chest. 2014. PMID: 24945194 Clinical Trial.
European EADV network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools.
Ständer S, Zeidler C, Riepe C, Steinke S, Fritz F, Bruland P, Soto-Rey I, Storck M, Agner T, Augustin M, Blome C, Dalgard F, Evers AW, Garcovich S, Gonçalo M, Lambert J, Legat FJ, Leslie T, Misery L, Raap U, Reich A, Şavk E, Streit M, Serra-Baldrich E, Szepietowski J, Wallengren J, Weisshaar E, Dugas M. Ständer S, et al. Among authors: misery l. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1144-7. doi: 10.1111/jdv.13296. Epub 2015 Sep 15. J Eur Acad Dermatol Venereol. 2016. PMID: 26370062
Sensitive skin.
Misery L, Loser K, Ständer S. Misery L, et al. J Eur Acad Dermatol Venereol. 2016 Feb;30 Suppl 1:2-8. doi: 10.1111/jdv.13532. J Eur Acad Dermatol Venereol. 2016. PMID: 26805416 Review.
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Among authors: misery l. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
637 results